Renal cancer, also known as renal cell carcinoma, originates from renal tubular epithelial cells in the kidney parenchyma. It is one of the most common malignant tumors in the urinary system. The incidence of renal cancer has been increasing in recent years, and it has become one of the major threats to human health. Currently, the main treatment of renal cancer is surgical resection, supplemented by immunotherapy and targeted drug therapy. Molecularly targeted therapy can specifically act on the lesion and reduce damage to normal tissues, which makes it a hot research topic of anti-cancer drugs. Targeted drugs for renal cancer mainly include tyrosine kinase inhibitors, monoclonal antibodies, protein inhibitors, etc.
With the wide application of molecular targeted drugs in clinical practice, although the objective response rate and progression-free survival can be effectively improved in patients with renal cancer, drug-related adverse effects in skin, cardiovascular, and digestive systems appear accordingly. In addition, drug resistance and the reduction of efficacy may occur with the continuous administration of molecularly targeted drugs. There is therefore an urgent clinical need for safer and more effective targeted therapeutic agents for renal cancer.
The Innovative Technology of Targeted Therapy for Kidney Disease
The renal disease targeting development platform self-designed by MicuRx enables the targeted distribution of chemically modified drug entities to the kidney. Under the renal microenvironment, the active drug dissociates and achieves the therapeutic effect. Compared with non-targeted therapy, this innovative technology not only assures the lower systemic exposure of active ingredients and reduction in toxicity, but also the increase of regional drug exposure in the kidney, which consequently enhances efficacy. Thus, this kidney-targeted therapy is expected to provide a safer and more effective option for patients.